New Guideline Recommends CYP2C19 Genotyping Before Clopidogrel Therapy
Lydia Kariuki, Managing Editor at American Pharmacogenomics Association, posted on LinkedIn:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”

Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Nov 20, 2026, 13:20Ilenia Calcaterra: The Inferior Thyroid Arteries as a Window Into Cardiovascular Risk
-
Nov 20, 2026, 13:03Does Being Fit Protect Against VTE? – RPTH Journal
-
Nov 20, 2026, 12:29Thirunavukkarasu Angappan: Antithrombin in ECMO – Two Datasets, Two Opposite Answers
-
Nov 20, 2026, 11:38Muhammad Kashif: Therapeutic Plasma Exchange – Key Concepts at a Glance
-
Nov 20, 2026, 11:33Tyler McConville: Why Hemostatic Function Matters More Than Cell Counts in Trauma and Transfusion
-
Nov 20, 2026, 11:28Stéphanie Forté: Bringing Cutting-Edge Genomic and Proteomic Tools to Sickle Cell Disease Patients
-
Nov 20, 2026, 11:19EHC Urges Equal Early Diagnosis for Bleeding Disorders
-
Nov 20, 2026, 11:14Pushpinder Singh: How Do We Know if Haemodialysis is Effective?
-
Nov 20, 2026, 11:09Neel Patel: Honoured to Serve Across Five Faculty Roles at Hematocon 2026